Investigational drug · Phase 3
Chiauranib
Also called: CS2164
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Soft Tissue Sarcoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
17
Any phase or sponsor naming "Chiauranib"
First trial start
2022
Aug 25, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Chiauranib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pancreatic Ductal Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Soft Tissue Sarcoma
Approved drugs for the same conditions: Pancreatic cancer · Sarcoma · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Chiauranib" as an intervention, largest first.
- Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal AdenocarcinomaPivotal-lookingNot yet recruiting
Chipscreen Biosciences, Ltd.Industry
NCT07445295 · 558 participants (planned) · Start Mar 31, 2026 · Primary completion Jun 30, 2028
Drug: Chiauranib; Toripalimab Injection and 4 more · For: Metastatic Pancreatic Ductal Adenocarcinoma
Sites: Shanghai, China
- Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian CancerPivotal-lookingStatus unknown
Chipscreen Biosciences, Ltd.Industry
NCT04921527 · 454 participants (planned) · Start Dec 20, 2021 · Primary completion Dec 31, 2024
Drug: chiauranib; Placebo and 1 more · For: Ovarian Cancer; Relapsed or Refractory; Chiauranib and 1 more
Sites: Shanghai, China
- Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung CancerPivotal-lookingCompleted
Chipscreen Biosciences, Ltd.Industry
NCT04830813 · 184 participants · Start Mar 5, 2021 · Primary completion Apr 1, 2024
Drug: Chiauranib; Placebo · For: Small Cell Lung Cancer
Sites: Beijing, China
Chipscreen Biosciences, Ltd.Industry
NCT03216343 · 48 participants · Start Nov 9, 2017 · Primary completion Nov 4, 2022
Drug: Chiauranib · For: Small Cell Lung Cancer
Sites: Beijing, China
Chipscreen Biosciences, Ltd.Industry
NCT03901118 · 47 participants · Start Jul 1, 2019 · Primary completion Dec 18, 2020
Drug: chiauranib; etoposide and 1 more · For: Ovarian Cancer
Sites: Shanghai, China
- Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal AdenocarcinomaActive, not recruiting
Chipscreen Biosciences, Ltd.Industry
NCT06492915 · 42 participants (planned) · Start Aug 13, 2024 · Primary completion Feb 28, 2027
Drug: Chiauranib; Albumin-paclitaxel Injection and 1 more · For: Pancreatic Ductal Adenocarcinoma
Sites: Shanghai, China
Chipscreen Biosciences, Ltd.Industry
NCT05497843 · 40 participants · Start Aug 25, 2022 · Primary completion Jan 3, 2025
Drug: Chiauranib · For: Soft Tissue Sarcoma
Sites: Guangzhou, China
AkesoIndustry
NCT05505825 · 36 participants · Start Aug 26, 2022 · Primary completion Jul 19, 2024
Drug: AK104 IV infusion;Chiauranib oral · For: SCLC,Extensive Stage
Sites: Westmead, Australia; South Brisbane, Australia; Woolloongabba, Australia · 7 sites in all
Chipscreen Biosciences, Ltd.Industry
NCT05271292 · 36 participants (planned) · Start Aug 26, 2022 · Primary completion Mar 2025
Drug: Chiauranib · For: Small Cell Lung Cancer; Advanced Solid Malignant Tumor
Sites: Encinitas, California; Fullerton, California; Atlanta, Georgia · 11 sites in all
Chipscreen Biosciences, Ltd.Industry
NCT03245190 · 27 participants · Start Apr 28, 2018 · Primary completion Nov 1, 2019
Drug: Chiauranib · For: Hepatocellular Carcinoma
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- CS2164 combined with radiation suppressed tumor growth via γ-H2AX persistence and ROS accumulation.
Peng SL, Zhou YL, Liang X, et al. · BMC Cancer 2026
- DGKα inhibition enhances the antitumor effect of chiauranib on transformed follicular lymphoma.
Huang J, Zhong M, Yao J, et al. · Ann Hematol 2025
- Efficacy and safety of chiauranib in a combination therapy in platinum-resistant or refractory ovarian cancer: a multicenter, open-label, phase Ib and II study.
Li J, Liu J, Yin R, et al. · Mol Cancer 2024
- Inhibition of extranodal NK/T-cell lymphoma by Chiauranib through an AIF-dependent pathway and its synergy with L-asparaginase.
Gao T, Huang J, Yin H, et al. · Cell Death Dis 2023
- In silico targeting of colony-stimulating factor-1 receptor: delineating immunotherapy in cancer.
Azhar Z, Grose RP, Raza A, et al. · Explor Target Antitumor Ther 2023
- Preclinical Studies of Chiauranib Show It Inhibits Transformed Follicular Lymphoma through the VEGFR2/ERK/STAT3 Signaling Pathway.
Tang Y, Zhong M, Pan G, et al. · Pharmaceuticals (Basel) 2022
Also in development for Pancreatic Ductal Adenocarcinoma
- AZD0901Sonesitatug vedotin, CMG901Phase 36 trials
AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma
- Supportive care measuresPhase 36 trials
Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
- AtebimetinibIMM-1-104, Group APhase 34 trials
Immuneering Corporation · Pancreatic Adenocarcinoma, Advanced Solid Tumor, Malignant Melanoma (Cutaneous)
- IBI343Arcotatug TavatecanPhase 34 trials
Innovent Biologics (Suzhou) Co. Ltd. · CLDN18.2 Positive, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Primary Gastric Adenocarcinoma
- NavlimetostatBMS-986504, MRTX1719Phase 34 trials
Bristol Myers Squibb · Pancreatic Ductal Adenocarcinoma, Metastatic Non-small Cell Lung Cancer With MTAP Deletion, Solid Tumors
- [18F]FAPI-74 PETPhase 33 trials
SOFIE · Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction
- SBP-101ivospeminPhase 31 trial
Panbela Therapeutics, Inc. · Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
- GFH276Phase 25 trials
Genfleet Therapeutics (Shanghai) Inc. · RAS Mutation, Pancreatic Cancer, Non-small Cell Lung Cancer (NSCLC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.